⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL791200 | 0.82 | — | — | |
| SCHEMBL29220546 | 0.82 | — | — | |
| SCHEMBL5519675 | 0.82 | — | — | |
| SCHEMBL533521 | 0.79 | ALDH1A1 (0.38) | — | |
| SCHEMBL970494 | 0.76 | — | — | |
| SCHEMBL8829945 | 0.71 | PTGS2 (0.39) | — | |
| SCHEMBL1031732 | 0.69 | — | — | |
| SCHEMBL7173690 | 0.69 | HRH3 (0.31) | — | |
| SCHEMBL14809357 | 0.69 | DPP4 (0.38) | — | |
| SCHEMBL179333 | 0.68 | LMNA (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3363788-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2018-08-22 | — | — | EP | claimed |
| US-20130165412-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2013-06-27 | — | — | US | claimed |
| US-20120214766-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. | 2012-08-23 | — | — | US | claimed |
| EP-2470508-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2012-07-04 | — | — | EP | claimed |
| WO-2011025541-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | WO | claimed |
| EP-1554239-B1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2011-01-26 | — | — | EP | claimed |
| US-7435815-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-10-14 | — | — | US | claimed |
| US-20070244156-A1 | SULFONYLAMINO-ACETIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-18 | — | — | US | claimed |
| US-7279578-B2 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2007-10-09 | — | — | US | claimed |
| US-20060014783-A1 | Sulfonylamino-acetic acid derivatives | ACTELION PHARMACEUTICALS, LTD. (CH) | 2006-01-19 | — | — | US | claimed |
| EP-1554239-A2 | SULFONYLAMINO-ACETIC ACID DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2005-07-20 | — | — | EP | claimed |
| WO-2004033418-A2 | SULFONYLAMINO-ACETIC DERIVATIVES AND THEIR USE AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-04-22 | — | — | WO | claimed |
| US-5856484-A | Sulfonylaminopyrimidine carboxylic acid derivatives having endothelin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 1999-01-05 | — | — | US | claimed |
| CN-117956985-A | Inhibitors of glycogen synthase 1 (GYS 1) and methods of use thereof | 梅兹治疗公司 | 2024-04-30 | — | — | CN | disclosed |
| US-20240115566-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | ST JUDE CHILDRENS RES HOSPITAL INC (US) | 2024-04-11 | — | — | US | disclosed |
| EP-4262814-A1 | METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR | St. Jude Children's Research Hospital, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| US-6242601-B1 | ENDOTHELIN RECEPTORS INHIBITORS SUCH AS 4-(4-METHOXY-5-(2-METHOXY-PHENOXY)-6-(5-METHYL-PYRIDINE-2-SULF ONYLAMINO)-PYRIMIDIN-2-YL)-PYRIDINE-2-CARBOXYLIC ACID USED TO TREAT CARDIOVASCULAR SYSTEM DISORDERS | HOFFMAN-LA ROCHE INC. | 2001-06-05 | — | — | US | disclosed |
| WO-2000052007-A1 | 4-HETEROCYCLYSULFONAMIDYL-6-METHOXY-5-(2-METHOXY-PHENOXY)-2-PYRIDYL-PYRIMIDINE DERIVATIVES, THEIR PREPARATION AND USE AS ENDOTHELIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000042035-A1 | 4-(HETEROCYCLYLSULFONAMIDO) -5-METHOXY-6- (2-METHOXYPHENOXY) -2-PHENYL- OR PYRIDYLPYRIMIDINES AS ENDOTHELIN RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2000-07-20 | — | — | WO | disclosed |
| US-5856484-A | Sulfonylaminopyrimidine carboxylic acid derivatives having endothelin inhibiting activity | HOFFMANN-LA ROCHE INC. (US) | 1999-01-05 | — | — | US | disclosed |